SBIH "Moscow Clinical Scientific and Practical Center named after A.S. Loginov of DHM”, Moscow, Russian Federation
Katerina Grechukhina , Natalia Chebotareva , Tatyana Krasnova , Lyudmila Zhukova
Background: Anti-angiogenic anticancer drugs that block VEGF can cause kidney damage (Fujii et al., 2019). Among the mechanisms of nephrotoxicity thrombotic microangiopathy (TMA) of renal vessels can be distinguished (Estrada et al., 2019). TMA can be accompanied the development of anemia, excessive schistocytes, as well as increased LDH levels and a low platelet count, which indicated the occurrence of endothelial dysfunction and microangiopathic processes (Hauser et al, 2009). The goal of this study was to assess the risk factors of early nephrotoxicity and the utility of NGAL, KIM-1, HIF-1α and nephrin levels in urine as early biomarkers of nephrotoxicity. Methods: The study included 50 patients who received anti-VEGF drugs (aflibercept, bevacizumab or ramucirumab). Nephrotoxicity was determined as a decrease in glomerular filtration rate (GFR) to < 60 ml/min/1.73m2 at 8 weeks from the initiation of therapy. The laboratory parameters and the levels of KIM-1, NGAL, HIF-1α and nephrin in urine samples were determined by ELISA before treatment and after 1, 2, 4 and 8 weeks of treatment. To assess risk factors for nephrotoxicity we analyzed primary clinical and laboratory parameters. Results: Nephrotoxicity at 8 weeks was achieved in 21 (42%) of patients. A statistically significant decrease in hemoglobin and platelet count by 20 and 26%, respectively, from the initial level was observed. An increase in the number of schistocytes and a slight increase in LDH levels were also observed. The increase in NGAL, KIM-1 and nephrin levels was statistically significant in 1 weeks and the increase of HIF-1α in 2 weeks after the start of therapy (p = 0.001). The unfavorable predictors of nephrotoxicity as well as the favorable predictors in terms of decreasing renal function are presented in Table. ROC analysis demonstrated high sensitivity and specificity: NGAL – AUC 0.7; KIM-1 – AUC 0.69; HIF-1α– 0.7; nephrin – AUC 0.7. Conclusions: We report a significant increase in the parameters of microangiopathic hemolysis and in urine biomarkers of tubular and podocytic damage as well as hypoxia by the 8th week of treatment. We suggest that the TMA process can take part in renal damage. Increased levels of NGAL, KIM-1, HIF-1α and nephrin in the urine reflect the renal damage processes and have higher sensitivity and specificity then serum creatitine. The independent risk factors for nephrotoxicity are determined.
Predictors of early nephrotoxicity of anti-VEGF drugs. | |||
---|---|---|---|
Factor | Odds ratio | 95% confidence interval | P value |
Unfavorable predictors | |||
Initial decrease in estimated GFR less than 100 ml/min/1.73m2 | 3.25 | 1.36-9.97 | 0.004 |
History of arterial hypertension | 1.50 | 1.44-1.99 | 0.013 |
Increase of NGAL, KIM-1 in 1 week and HIF-1α in 2 weeks in urine after the initiation of treatment | 7.80 | 1.30-35.55 | 0.010 |
Favorable predictors | |||
Adequate control of hypertension | 0.13 | 0.04-0.36 | 0.001 |
Normal level of D-dimer during 8 weeks | 0.31 | 0.09-0.80 | 0.040 |
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2023 ASCO Annual Meeting
First Author: Natalia Chebotareva
2024 ASCO Annual Meeting
First Author: Shereef Ahmed Elsamany
2024 ASCO Genitourinary Cancers Symposium
First Author: Ekamjit Singh Deol